Market Closed -
Nasdaq
16:00:00 2024-05-09 EDT
|
5-day change
|
1st Jan Change
|
21.56
USD
|
+2.47%
|
|
+3.90%
|
-4.73%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
287.8
|
720.9
|
626.1
|
604.6
|
-
|
-
|
Enterprise Value (EV)
1 |
233.6
|
591.7
|
626.1
|
541.6
|
611.4
|
604.6
|
P/E ratio
|
-6.3
x
|
-14
x
|
-7.89
x
|
-6.96
x
|
-6.87
x
|
-7.09
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
161
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
161
x
|
EV / EBITDA
|
-
|
-11,128,828
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-8.47
x
|
-15
x
|
-
|
-6.69
x
|
-7.07
x
|
-8.58
x
|
FCF Yield
|
-11.8%
|
-6.64%
|
-
|
-15%
|
-14.1%
|
-11.7%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
24,410
|
24,605
|
27,669
|
28,737
|
-
|
-
|
Reference price
2 |
11.79
|
29.30
|
22.63
|
21.04
|
21.04
|
21.04
|
Announcement Date
|
22-03-30
|
23-03-29
|
24-03-25
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
3.767
|
EBITDA
|
-
|
-
|
-53.17
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-23.02
|
-53.24
|
-81.41
|
-92.49
|
-102.5
|
-106.7
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,832.05%
|
Earnings before Tax (EBT)
1 |
-
|
-22.96
|
-51.49
|
-75.46
|
-88.32
|
-99.24
|
-103.2
|
Net income
1 |
-9.611
|
-22.96
|
-51.51
|
-75.52
|
-89.04
|
-99.56
|
-103.3
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,741.92%
|
EPS
2 |
-40.32
|
-1.870
|
-2.100
|
-2.870
|
-3.023
|
-3.062
|
-2.968
|
Free Cash Flow
1 |
-
|
-27.58
|
-39.32
|
-
|
-81
|
-86.5
|
-70.5
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,871.68%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-05-06
|
22-03-30
|
23-03-29
|
24-03-25
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-6.2
|
-8.268
|
-11.02
|
-12.22
|
-14.15
|
-15.85
|
-17.64
|
-20.34
|
-21.37
|
-22.07
|
-22.22
|
-22.75
|
-23.32
|
-23.92
|
-26.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-6.184
|
-8.22
|
-10.91
|
-11.99
|
-13.59
|
-15
|
-16.52
|
-19.02
|
-19.56
|
-20.36
|
-21.09
|
-21.65
|
-22.27
|
-22.9
|
-24.3
|
Net income
1 |
-6.184
|
-8.223
|
-10.91
|
-11.99
|
-13.59
|
-15.02
|
-16.52
|
-19.02
|
-19.56
|
-20.41
|
-21.37
|
-21.91
|
-22.49
|
-23.09
|
-24.3
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.2600
|
-0.0700
|
-0.4500
|
-0.4900
|
-0.5600
|
-0.6100
|
-0.6700
|
-0.7600
|
-0.7100
|
-0.7400
|
-0.7650
|
-0.7500
|
-0.7483
|
-0.7617
|
-0.6800
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-15
|
22-03-30
|
22-05-16
|
22-08-15
|
22-11-14
|
23-03-29
|
23-05-15
|
23-08-14
|
23-11-13
|
24-03-25
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
6.79
|
-
|
Net Cash position
1 |
-
|
54.2
|
129
|
-
|
63.1
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-27.6
|
-39.3
|
-
|
-81
|
-86.5
|
-70.5
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
0.18
|
0.2
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-05-06
|
22-03-30
|
23-03-29
|
24-03-25
|
-
|
-
|
-
|
Last Close Price
21.04
USD Average target price
44.67
USD Spread / Average Target +112.29% Consensus |
1st Jan change
|
Capi.
|
---|
| -4.73% | 605M | | +23.37% | 46.71B | | +48.83% | 41.8B | | -0.94% | 41.52B | | -5.86% | 29.55B | | +11.29% | 25.78B | | -20.92% | 19.26B | | +3.20% | 12.14B | | -2.67% | 12.08B | | +30.23% | 11.98B |
Other Biotechnology & Medical Research
|